Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled phase 2 study of opicinumab added to anti-inflammatory disease-modifying therapy in relapsing multiple sclerosis
MOH_2018-02-15_002192Phase 2Not yet recruiting
- Sponsor
- Biogen
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS) comparing Opicinumab IV with Placebo IV (2 arms). Planned start Jan 2018; status: not yet recruiting.
02
Drugs
opicinumab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on MOH_2018-02-15_002192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-15_002192.